

Policy: MP214

Section: Medical Benefit Policy

Subject: Iontophoresis

I. Policy: Iontophoresis

II. Purpose/Objective:

To provide a policy of coverage regarding Iontophoresis

III. Responsibility:

- A. Medical Directors
- B. Medical Management

IV. Required Definitions

1. Attachment – a supporting document that is developed and maintained by the policy writer or department requiring/authoring the policy.
2. Exhibit – a supporting document developed and maintained in a department other than the department requiring/authoring the policy.
3. Devised – the date the policy was implemented.
4. Revised – the date of every revision to the policy, including typographical and grammatical changes.
5. Reviewed – the date documenting the annual review if the policy has no revisions necessary.

V. Additional Definitions

Medical Necessity or Medically Necessary means Covered Services rendered by a Health Care Provider that the Plan determines are:

- a. appropriate for the symptoms and diagnosis or treatment of the Member's condition, illness, disease or injury;
- b. provided for the diagnosis, and the direct care and treatment of the Member's condition, illness disease or injury;
- c. in accordance with current standards of good medical treatment practiced by the general medical community.
- d. not primarily for the convenience of the Member, or the Member's Health Care Provider; and
- e. the most appropriate source or level of service that can safely be provided to the Member. When applied to hospitalization, this further means that the Member requires acute care as an inpatient due to the nature of the services rendered or the Member's condition, and the Member cannot receive safe or adequate care as an outpatient.

Medicaid Business Segment

Medical Necessity shall mean a service or benefit that is compensable under the Medical Assistance Program and if it meets any one of the following standards:

- (i) The service or benefit will, or is reasonably expected to, prevent the onset of an illness, condition or disability.
- (ii) The service or benefit will, or is reasonably expected to, reduce or ameliorate the physical, mental or development effects of an illness, condition, injury or disability.
- (iii) The service or benefit will assist the Member to achieve or maintain maximum functional capacity in performing daily activities, taking into account both the functional capacity of the Member and those functional capacities that are appropriate for members of the same age.

DESCRIPTION:

Iontophoresis a method of transdermal local drug delivery using an electrical current. When drug and the Iontophoresis setting have the same polarity, drug molecules are forced into the skin by electrostatic repulsion.

INDICATIONS:

Transdermal local drug delivery utilizing Iontophoresis for the treatment of musculoskeletal inflammation resulting in pain and/or edema is considered to be medically necessary only when used as part of an overall treatment protocol in **any of the following** conditions:

- Epicondylitis
- Patellofemoral syndrome
- Tendonitis (except Achilles tendonitis)
- Rotator cuff syndrome
- Plantar fasciitis

Iontophoresis for the treatment of Primary Focal hyperhidrosis is considered to be medically necessary when insured individual is unresponsive to topicals and pharmacologics (e.g. Topical chloride, anti-cholinergics, beta-blockers, benzodiazapines) (**see MP258 Hyperhidrosis**)

Iontophoresis for the administration of local anesthesia prior to a venipuncture or dermatological procedures is considered to be medically necessary for pain reduction.

EXCLUSIONS:

The Plan does NOT provide coverage for Iontophoresis as a transdermal drug delivery technique for other medical indications because it is considered unproven.

The Plan does **NOT** provide coverage for *Iontophoresis* as a “stand-alone” treatment for any indication because it is considered **unproven**. Although the currently available literature regarding the use of *Iontophoresis* is encouraging, the studies have been conducted under varying conditions and protocols, making it impossible to establish superiority in effectiveness of this technology on health outcomes when compared to established technologies or treatments.

Note: A complete description of the process by which a given technology or service is evaluated and determined to be experimental, investigational or unproven services is outlined in **MP 15 – Experimental, Investigational or Unproven Services or Treatment**

CODING ASSOCIATED WITH: Iontophoresis

The following codes are included below for informational purposes and may not be all inclusive. Inclusion of a procedure or device code(s) does not constitute or imply coverage nor does it imply or guarantee provider reimbursement. Coverage is determined by the member specific benefit plan document and any applicable laws regarding coverage of specific services. Please note that per Medicare coverage rules, only specific CPT/HCPCS Codes may be covered for the Medicare Business Segment. Please consult the CMS website at www.cms.gov or the local Medicare Administrative Carrier (MAC) for more information on Medicare coverage and coding requirements.

97033 Application of a modality to one or more areas; Iontophoresis, each 15 minutes.

Current Procedural Terminology (CPT®) © American Medical Association: Chicago, IL

LINE OF BUSINESS:

Eligibility and contract specific benefits, limitations and/or exclusions will apply. Coverage statements found in the line of business specific benefit document will supersede this policy. For Medicare, applicable LCD's and NCD's will supercede this policy. For PA Medicaid Business segment, this policy applies as written.

REFERENCES:

Geisinger Technology Assessment Triage Committee. Iontophoresis. March 26, 2008.

Li GL, Van Steeg TJ, Putter H, Van Der Spek J, Pavel S, Danhoff and Bouwstra JA. Cutaneous side-effects of transdermal Iontophoresis with and without surfactant pretreatment: a single-blinded, randomized, controlled trial. Br J Dermatology 2005;153:404-412.

Gordon BI, Maibach HI. Eccrine anhidrosis due to glutaraldehyde, formaldehyde and iontophoresis. *J Invest Dermatol* 1969; 53:436-9.

Karakoc Y, Aydemir EH, Kalkan MT. Placebo-controlled evaluation of direct electrical current administration for palmo-plantar hyperhidrosis. *Int J Dermatol*. 2004 Jul; 43(7):503-5.

Aydemir EH, Kalkan MT, Karakoc Y. Quantitative effect of anodal current in the treatment of primary hyperhidrosis by direct electrical current. *Int J Dermatol*. 2006 Jul; 45(7):862-4.

Hornberger, J., Grimes, K, Naumann, M, Glaser, D.A., et al. Recognition, diagnosis, and treatment of primary focal hyperhidrosis. *J Am Acad Dermatol* 2004; 51:274-86.

Solish, N, Bertucci, V, Dansereau, A, Hong, HC, Lynde, C, Lupin, M, Smith, KC, and Storwick, G. A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee. *Dermatol Surg*. 2007;33(8):908-923

TEC Assessment: Iontophoresis for Medical Indications. 2003; BlueCross and BlueShield Association Technology Evaluation Center, Vol 18, Tab 3

Kassan DG, Lynch AM, Stiller MJ. Physical enhancement of dermatologic drug delivery: iontophoresis and phonophoresis. *J Am Acad Dermatol* 1996;38(4):657-666.

Aygul R, Ulvi H, Karatay S, Deniz O, Varoglu AO. Determination of sensitive electrophysiologic parameters at follow-up of different steroid treatments of carpal tunnel syndrome. *J Clin neurophysiol* 2005 June;22(3):222-30.

Osborne HR and Allision GT. Treatment of plantar fasciitis by LowDye taping and iontophoresis: short term results of a double blinded randomized., placebo controlled clinical trial of dexamethasone and acetic acid. *Br J Sports med* 2006;40:545-549.

ECRI Institute (online) Custom Hotline Response. Iontophoresis for drug delivery in physical medicine and rehabilitation settings. April 24, 2006. Accessed on February 15, 2008.

Cerfolio RJ, De Campos JRM, Bryant AS, et al. The Society of Thoracic Surgeons Expert Consensus for the Surgical Treatment of Hyperhidrosis. *Ann Thorac Surg* 2011; 91:1642-1648

Nirschl RP, Rodin DM, Ochiai DH, Maartmann-Moe C. Iontophoretic administration of dexamethasone sodium phosphate for acute epicondylitis. A randomized, double-blinded, placebo-controlled study. *Am J Sports Med*. 2003; 31(2):189-195.

Runeson L, Haker E. Iontophoresis with cortisone in the treatment of lateral epicondylalgia (tennis elbow)--a double-blind study. *Scand J Med Sci Sports*. 2002;12(3):136-42

Leduc BE, Caya J, Tremblay S, Bureau NJ, Dumont M. Treatment of calcifying tendinitis of the shoulder by acetic acid iontophoresis: a double-blind randomized controlled trial. *Archives of physical medicine and rehabilitation*. 2003;84(10):1523-7. Cochrane Library CN-00453250

Baskurt F, Ozcan A, Algun C. Comparison of effects of phonophoresis and iontophoresis of naproxen in the treatment of lateral epicondylitis. *Clin Rehabil*. 2003;17(1):96-100.

Smith CC, Pariser D. Primary focal hyperhidrosis. UpToDate Inc., Waltham, MA. Last reviewed February 2018

da Rocha FR, Haupenthal DPDS, Zaccaron RP, et al. Therapeutic effects of iontophoresis with gold nanoparticles in the repair of traumatic muscle injury. *J Drug Target*. 2019 Aug 16:1-13

Kazemi M, Mombeiny R, Tavakol S, et al. A combination therapy of nanoethosomal piroxicam formulation along with iontophoresis as an anti-inflammatory transdermal delivery system for wound healing. *Int Wound J*. 2019;16(5):1144-1152.

Lombardo M, Serrao S, Lombardo G, Schiano-Lomoriello D. Two-year outcomes of a randomized controlled trial of transepithelial corneal crosslinking with iontophoresis for keratoconus. *J Cataract Refract Surg*. 2019; 45(7):992-1000.

Vinciguerra P, Rosetta P, Legrottaglie EF, et al. Iontophoresis CXL with and without epithelial debridement versus standard CXL: 2-year clinical results of a prospective clinical study. *J Refract Surg*. 2019; 35(3):184-190.

This policy will be revised as necessary and reviewed no less than annually.

Devised: 03/27/08

Revised: 9/12 (added indications), 10/14 (added hyperhidrosis as indication), 9/19 (Updated Indication Language); 9/20 (clarify indications and exclusion); 9/21(indication clarification)

Reviewed: 9/11, 10/13, 10/15, 10/16, 9/17, 9/18

Geisinger Health Plan may refer collectively to health care coverage sponsors Geisinger Health Plan, Geisinger Quality Options, Inc., and Geisinger Indemnity Insurance Company, unless otherwise noted. Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

Coverage for experimental or investigational treatments, services and procedures is specifically excluded under the member's certificate with Geisinger Health Plan. Unproven services outside of an approved clinical trial are also specifically excluded under the member's certificate with Geisinger Health Plan. This policy does not expand coverage to services or items specifically excluded from coverage in the member's certificate with Geisinger Health Plan. Additional information can be found in MP015 Experimental, Investigational or Unproven Services.

Prior authorization and/or pre-certification requirements for services or items may apply. Pre-certification lists may be found in the member's contract specific benefit document. Prior authorization requirements can be found at <https://www.geisinger.org/health-plan/providers/ghp-clinical-policies>

Please be advised that the use of the logos, service marks or names of Geisinger Health Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company on a marketing, press releases or any communication piece regarding the contents of this medical policy is strictly prohibited without the prior written consent of Geisinger Health Plan. Additionally, the above medical policy does not confer any endorsement by Geisinger Health Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company regarding the medical service, medical device or medical lab test described under this medical policy.